Effect Narrow-Band UVB Radiations

NCT05647187 | Completed

• 1 other identifier: SVU.MED.DVA021, Code 1, N76
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

Narrow-band UVR affects Interleukin 17 which has a major role in the pathogenesis of psoriasis Vulgaris. the aim of this study to evaluate the serum levels of Interleukin 17 in psoriatic patients and compare with the levels in healthy controls \& evaluate the effect of narrow-band ultraviolet B (NB-UVB) on the serum of Interleukin 17 and the treatment of psoriasis Vulgaris.

Conditions

Psoriasis Vulgaris; UVB Phototherapy Burn

Keywords

Psoriasis vulgaris; UVB radiations; Interleukin 17

Outcome Measures

Primary Outcomes (1)

• Primary (main):

  To evaluate the clinical efficacy of narrow-band ultraviolet B (NB-UVB) in treatment of psoriasis vulgaris , evaluate serum levels of Interleukin 17 in psoriatic patients and compare them with levels in healthy controls

  12 weeks

Secondary Outcomes (1)

• Secondary (subsidiary)

  12 weeks

Study Arms (2)

NB-UVB group

ACTIVE COMPARATOR

fourty patients will be treated with NB-UVB. The initial radiation dose was determined according to the patient's skin type; initial dose will be increased by 20% per session. Sessions will be given three times weekly with 48 hours apart for three months.

Diagnostic Test: Serum Interleukin 17 levels; Radiation: NB-UVB

Control group

NO INTERVENTION

fourty healthy controls without psoriasis , any family history of psoriasis or any dermatological diseases.

Interventions

Serum Interleukin 17 levels DIAGNOSTIC_TEST

Serum Interleukin 17 levels will be measured pre and post treatment by NB-UVB by performing an enzyme-linked immune sorbent assay (ELISA)

Also known as: NB-UVB

NB-UVB group

NB-UVB RADIATION

patients will be exposed to narrow band UVB twice weekly for three months

NB-UVB group

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with psoriasis diagnosed clinically

You may not qualify if:

• Patient with history of skin cancer. Patient with history of photosensitivity. Patient receiving immune suppressive drugs .

Sponsors & Collaborators

• South Valley University: lead

Study Sites (1)

South Valley University

Qina, Qena Governorate, 83522, Egypt

Location

Study Officials

• Hassan M Ibrahim, professor

  South Valley University

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate professor of dermatology

Study Record Dates

• First Submitted: December 1, 2022
• First Posted: December 12, 2022
• Study Start: January 1, 2020
• Primary Completion: July 1, 2021
• Study Completion: October 1, 2021
• Last Updated: December 12, 2022

Record last verified: 2022-12

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)